Unlocking the power of lectins: BOA emerges as a potent weapon against all SARS-CoV-2 variants

Researchers discover that antiviral lectins like BOA can effectively inhibit SARS-CoV-2 and its variants by targeting spike glycans, opening doors for potential pan-coronavirus treatments. The study reveals that BOA’s multivalent interactions make it a potent inhibitor against a range of viral variants, offering promise for future therapeutic strategies.

Two newly discovered mechanisms in bacteria can contribute to antibiotic resistance

Two newly discovered mechanisms in bacteria have been identified that can contribute to the development of antibiotic resistance.

May 20, 2024

Once a scientific backwater, protein research attracts billion-dollar deals and high-profile publications

When it comes to detecting disease and understanding how the body works, protein research has long been overshadowed by DNA sequencing. But the field, known

February 24, 2024

Catalent had several suitors, including another of its business partners, before Novo won out

In 2022, about nine months before Novo Holdings first reached out to Catalent about a potential deal, the contract manufacturer was in talks with another

April 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.